He Huang
CAR-T cells chimeric antigen receptor T cells(He Huang)은 FRα 표적 세포·유전자 치료로, Relapsed/Refractory Acute Myeloid Leukemia(AML) 영역에서 개발·상용화 중입니다. 작용기전: targeting B cell maturation antigen. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: 0% (ClinicalTrials.gov NCT05714345). 차별점: novel bridging strategies to eliminate MRD and enable transplant are urgently needed.
FRα
Relapsed/Refractory Acute Myeloid Leukemia(AML)
Recruiting
bispecific antibodies, and chimeric antigen receptor T cells
lentiviral expression vector and removed epitope tags used to discriminate between CAR and
humanized antibody capable of recognizing both LILRB3 and LILRB4
novel bridging strategies to eliminate MRD and enable transplant are urgently needed
targeting B cell maturation antigen
cytokine release syndrome occurred on day 3 and resolved with management; no neurotoxicity was observed
biomarker-driven methods were among the clinically orientated themes that emerged from foundational and precl
resistance to dominant suppressive pathways such as TGF-β and adenosine signalling, improved trafficking and tissue penetration
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
He Huang
CAR-T cells chimeric antigen receptor T cells(He Huang)은 FRα 표적 세포·유전자 치료로, Relapsed/Refractory Acute Myeloid Leukemia(AML) 영역에서 개발·상용화 중입니다. 작용기전: targeting B cell maturation antigen. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: 0% (ClinicalTrials.gov NCT05714345). 차별점: novel bridging strategies to eliminate MRD and enable transplant are urgently needed.
FRα
Relapsed/Refractory Acute Myeloid Leukemia(AML)
Recruiting
bispecific antibodies, and chimeric antigen receptor T cells
lentiviral expression vector and removed epitope tags used to discriminate between CAR and
humanized antibody capable of recognizing both LILRB3 and LILRB4
novel bridging strategies to eliminate MRD and enable transplant are urgently needed
targeting B cell maturation antigen
cytokine release syndrome occurred on day 3 and resolved with management; no neurotoxicity was observed
biomarker-driven methods were among the clinically orientated themes that emerged from foundational and precl
resistance to dominant suppressive pathways such as TGF-β and adenosine signalling, improved trafficking and tissue penetration
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.